For example, 66.7% (42/63) of putative therapeutic target HAMPs are largely uncharacterized with limited indications about how these genes influence cell biology and cancer, although many of these understudied HAMPs are recurrently altered among cancers, such as BRD9, BRD1, BPTF, and ATAD2 (Fig. 7e). This evidence concerns the gene ATAD2 and cancer.